These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21857512)

  • 1. Update in treatment of Chagas disease.
    Le Loup G; Pialoux G; Lescure FX
    Curr Opin Infect Dis; 2011 Oct; 24(5):428-34. PubMed ID: 21857512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Part VI. Antiparasitic treatment for Chagas disease].
    B WA; G IH; L MI; M LJ; V PM; H IN; V AM; P JS; H MT; A IZ
    Rev Chilena Infectol; 2008 Oct; 25(5):384-9, discussion 387. PubMed ID: 18949153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chagas disease: Present status of pathogenic mechanisms and chemotherapy.
    Maya JD; Orellana M; Ferreira J; Kemmerling U; López-Muñoz R; Morello A
    Biol Res; 2010; 43(3):323-31. PubMed ID: 21249304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
    Urbina JA
    J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease.
    Corrales M; Cardozo R; Segura MA; Urbina JA; Basombrío MA
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1556-60. PubMed ID: 15793138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country.
    Murcia L; Carrilero B; Muñoz MJ; Iborra MA; Segovia M
    J Antimicrob Chemother; 2010 Aug; 65(8):1759-64. PubMed ID: 20542903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease.
    Olivieri BP; Molina JT; de Castro SL; Pereira MC; Calvet CM; Urbina JA; Araújo-Jorge TC
    Int J Antimicrob Agents; 2010 Jul; 36(1):79-83. PubMed ID: 20452188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of Chagas disease chemotherapy.
    Guedes PM; Silva GK; Gutierrez FR; Silva JS
    Expert Rev Anti Infect Ther; 2011 May; 9(5):609-20. PubMed ID: 21609270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression and Chagas disease: a management challenge.
    Pinazo MJ; Espinosa G; Cortes-Lletget C; Posada Ede J; Aldasoro E; Oliveira I; Muñoz J; Gállego M; Gascon J
    PLoS Negl Trop Dis; 2013; 7(1):e1965. PubMed ID: 23349998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy].
    Gallerano RR; Sosa RR
    Rev Fac Cien Med Univ Nac Cordoba; 2000; 57(2):135-62. PubMed ID: 12934232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
    Viotti R; Vigliano C; Lococo B; Alvarez MG; Petti M; Bertocchi G; Armenti A
    Expert Rev Anti Infect Ther; 2009 Mar; 7(2):157-63. PubMed ID: 19254164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains.
    Cencig S; Coltel N; Truyens C; Carlier Y
    Int J Antimicrob Agents; 2012 Dec; 40(6):527-32. PubMed ID: 23063742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitrypanosomal therapy for chronic Chagas' disease.
    Bern C
    N Engl J Med; 2011 Jun; 364(26):2527-34. PubMed ID: 21714649
    [No Abstract]   [Full Text] [Related]  

  • 17. [Update on the treatment of Chagas' disease].
    Apt W; Zulantay I
    Rev Med Chil; 2011 Feb; 139(2):247-57. PubMed ID: 21773664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current drug therapy and pharmaceutical challenges for Chagas disease.
    Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
    Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic Chagas' disease: effects of treatment nn the levels of antibodies to crude and partially purified Trypanosoma cruzi antigens].
    Moretti E; Cervetta L; Basso B; Castro I; Santamarina N
    Bol Chil Parasitol; 1998; 53(1-2):3-9. PubMed ID: 9830716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American trypanosomiasis (Chagas disease).
    Rassi A; Rassi A; Marcondes de Rezende J
    Infect Dis Clin North Am; 2012 Jun; 26(2):275-91. PubMed ID: 22632639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.